Please login to the form below

Not currently logged in
Email:
Password:

Stemcentrx

This page shows the latest Stemcentrx news and features for those working in and with pharma, biotech and healthcare.

European biosimilars hit AbbVie’s Humira revenues in Q4

European biosimilars hit AbbVie’s Humira revenues in Q4

The company paid $5.8 billion to acquire the antibody drug conjugate and its developer Stemcentrx in 2016, and has already had to write off 4bn in asset impairment charges.

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Not content with the Stemcentrx acquisition, in April AbbVie also closed two other oncology deals:. ... Licensor/Acquisition target. Licensee/Acquirer. Deal type. Product technology.  Headline $m. Stemcentrx (US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics